Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Mikkel Højlund & Christoph U. Correll. (2023) Switching to long-acting injectable antipsychotics: pharmacological considerations and practical approaches. Expert Opinion on Pharmacotherapy 24:13, pages 1463-1489.
Read now
Read now
Georgios D. Kotzalidis, Chiara Rapinesi, Chiara Chetoni & Sergio De Filippis. (2021) Aripiprazole IM depot as an option for the treatment of bipolar disorder. Expert Opinion on Pharmacotherapy 22:11, pages 1407-1416.
Read now
Read now
Adrian Preda & Bryan B. Shapiro. (2020) A safety evaluation of aripiprazole in the treatment of schizophrenia. Expert Opinion on Drug Safety 19:12, pages 1529-1538.
Read now
Read now
Hanlan Liu, Jayaprakasam Bolleddula, Andrew Nichols, Lei Tang, Zhiyang Zhao & Chandra Prakash. (2020) Metabolism of bioconjugate therapeutics: why, when, and how?. Drug Metabolism Reviews 52:1, pages 66-124.
Read now
Read now
Leslie Citrome. (2017) Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications. Expert Review of Neurotherapeutics 17:10, pages 1029-1043.
Read now
Read now
Articles from other publishers (22)
Bhaskar Rege, James McGrory, Sabina Gasper & David McDonnell. (2022) Comment on “An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia”. PharmacoEconomics 40:12, pages 1261-1263.
Crossref
Crossref
Parisa Amani, Razieh Habibpour & Leila Karami. (2022) Characterizing aripiprazole and its ester derivatives, lauroxil and cavoxil, in interaction with dopamine D2 receptor: Molecular docking and dynamics simulations with physicochemical appraisals. Journal of Molecular Liquids 362, pages 119787.
Crossref
Crossref
George T. Kannarkat, Stanley N. Caroff & James F. Morley. (2022) Risk of Drug-induced Movement Disorders with Newer Antipsychotic Agents. Tremor and Other Hyperkinetic Movements 12:1.
Crossref
Crossref
Roger W. Sommi, Bhaskar Rege, Angela Wehr, Sejal Faldu, Yangchun Du & Peter J. Weiden. (2020) Aripiprazole Lauroxil Dosing Regimens: Understanding Dosage Strengths and Injection Intervals. CNS Spectrums 27:3, pages 262-267.
Crossref
Crossref
Jin Xiang, Nan Xu, Xueyan Wang, Songfan LI, Qin Yu, Maozhi Liang, Feng Nan, Shiqing Shu, Rui Yan, Yuqi Zhu & Linchuan Liao. (2021) Bioequivalence of 2 Aripiprazole Orally Disintegrating Tablets in Healthy Chinese Volunteers Under Fasting and Fed Conditions. Clinical Pharmacology in Drug Development 10:8, pages 840-849.
Crossref
Crossref
Donald J. AbrahamPaul W. Erhardt, Rahul Khupse, Jeffrey G. Sarver & Brian J. Kress. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
1
105
.
Leslie Citrome. (2021) Long-acting injectable antipsychotics: what, when, and how. CNS Spectrums 26:2, pages 118-129.
Crossref
Crossref
Somaraju R. Kumar, Chetan H. Mehta & Usha Y. Nayak. (2021) Long-Acting Formulations: A Promising Approach for the Treatment of Chronic Diseases. Current Pharmaceutical Design 27:6, pages 876-889.
Crossref
Crossref
Leslie Citrome & Jan Volavka. (2021) Specific Anti-hostility Effects of Atypical Antipsychotics in Persons with Schizophrenia: From Clozapine to Cariprazine. Harvard Review of Psychiatry 29:1, pages 20-34.
Crossref
Crossref
Ece Ö. Bülbül, Ioannis D. Karantas, Mehmet E. Okur, Panoraia I. Siafaka & Neslihan Ü. Okur. (2020) Schizophrenia; A Review on Promising Drug Delivery Systems. Current Pharmaceutical Design 26:31, pages 3871-3883.
Crossref
Crossref
Yu-Chul Kim, Kyoung Ah Min, Dong-Jin Jang, Tae Young Ahn, Jae Hyeok Min, Byeong Eun Yu & Kwan Hyung Cho. (2019) Practical approaches on the long-acting injections. Journal of Pharmaceutical Investigation 50:2, pages 147-157.
Crossref
Crossref
Christoph U. Correll, Jennifer Kern Sliwa, Dean M. Najarian & Stephen R. Saklad. (2018) Practical considerations for managing breakthrough psychosis and symptomatic worsening in patients with schizophrenia on long-acting injectable antipsychotics. CNS Spectrums 24:4, pages 354-370.
Crossref
Crossref
Brian J. Miller, Amy Claxton, Yangchun Du, Peter J. Weiden & Steven G. Potkin. (2019) Switching patients with schizophrenia from paliperidone palmitate to aripiprazole lauroxil: A 6-month, prospective, open-label study. Schizophrenia Research 208, pages 44-48.
Crossref
Crossref
SARAH FARWICK, MAGALI B. HICKEY, GWEN JACOBS, SEJAL P. FALDU, JENNIFER VANDIVER & PETER J. WEIDEN. (2019) Best Practices for Aripiprazole Lauroxil Administration: From Formulation Development to Injection Technique. Journal of Psychiatric Practice 25:2, pages 82-90.
Crossref
Crossref
Leslie Citrome, Robert Risinger, Andrew J. Cutler, Yangchun Du, Jacqueline Zummo, Henry A. Nasrallah & Bernard L. Silverman. (2017) Effect of aripiprazole lauroxil in patients with acute schizophrenia as assessed by the Positive and Negative Syndrome Scale—supportive analyses from a Phase 3 study. CNS Spectrums 23:4, pages 284-290.
Crossref
Crossref
Wei Chen, Bryant C. Yung, Zhiyong Qian & Xiaoyuan Chen. (2018) Improving long-term subcutaneous drug delivery by regulating material-bioenvironment interaction. Advanced Drug Delivery Reviews 127, pages 20-34.
Crossref
Crossref
Dong-Jing Fu, Ibrahim Turkoz, David Walling, Jean-Pierre Lindenmayer, Nina R. Schooler & Larry Alphs. (2018) Paliperidone palmitate once-monthly maintains improvement in functioning domains of the Personal and Social Performance scale compared with placebo in subjects with schizoaffective disorder. Schizophrenia Research 192, pages 185-193.
Crossref
Crossref
James E. Frampton. (2017) Aripiprazole Lauroxil: A Review in Schizophrenia. Drugs 77:18, pages 2049-2056.
Crossref
Crossref
Marjie L. HardRichard J. MillsBrian M. SadlerRyan Z. TurncliffLeslie Citrome. (2017) Aripiprazole Lauroxil. Journal of Clinical Psychopharmacology 37:3, pages 289-295.
Crossref
Crossref
Xinyi Tan, Yue Zhong, Luying He, Yuanyuan Zhang, Guanghui Jing, Song Li, Jing Wang, Haibing He & Xing Tang. (2016) Morphological and Crystalline Transitions in Monohydrous and Anhydrous Aripiprazole for a Long-Acting Injectable Suspension. AAPS PharmSciTech 18:4, pages 1270-1276.
Crossref
Crossref
Leslie Citrome. (2017) Emerging pharmacological therapies in schizophrenia: what’s new, what’s different, what’s next?. CNS Spectrums 21:S1, pages 1-12.
Crossref
Crossref
L. Citrome. (2016) What's in a name? Use of brand vs. generic drug names. International Journal of Clinical Practice 70:1, pages 3-4.
Crossref
Crossref